Actively Recruiting
Optimizing Pembrolizumab Use After Complete Response in Early Triple-Negative Breast Cancer A Randomized Study Comparing Treatment Duration and Outcomes
Led by UNICANCER · Updated on 2026-07-23
2454
Participants Needed
2
Research Sites
334 weeks
Total Duration
AI-Summary
What This Trial Is About
This trial is focused on patients with early triple-negative breast cancer, a type of breast cancer that lacks estrogen, progesterone, and HER2 receptors. The study aims to find out if stopping pembrolizumab treatment after a complete response to initial therapy is as effective as continuing pembrolizumab for an additional six months. Researchers also consider patients tolerance to treatment and their quality of life. Participants are randomly assigned to one of two groups one group receives pembrolizumab for six months, and the other group stops pembrolizumab after initial therapy. Following this, all patients will be monitored according to standard care practices for up to four years. The study is an open-label, phase III trial conducted internationally across multiple centers. During the study, participants will undergo regular assessments including toxicity monitoring, quality of life questionnaires, and survival tracking for up to eight years. Researchers will measure recurrence-free survival as the primary outcome while also evaluating treatment side effects, patient-reported outcomes, and various quality of life aspects. Long-term follow-up includes tracking menstruation recovery, pregnancy impact, and survival rates to provide a comprehensive understanding of treatment effects.
CONDITIONS
Brief Title
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
Research Team
S
Sonia Mardinian
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here